AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall St gains on chip stocks recovery; earnings draw focus
- Oil prices rise over 2% on fresh attacks by US and Iran
- Chip stocks extend global rebound following last week's rout
- Citi's Chew says U.S. stock positioning unwind may not be over
- Adobe, Salesforce and Intuit fall as Morgan Stanley begins cautious coverage
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- Intersnack to acquire Utz Brands at $14.25 per share in go-private deal
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
Amgen (AMGN) Reports In-Line Q4 EPS, Offers FY23 Guidance
January 31, 2023 4:03 PM ESTAmgen (NASDAQ: AMGN) reported Q4 EPS of $4.09, in-line with the analyst estimate of $4.09. Revenue for the quarter came in at $6.8 billion versus the consensus estimate of $6.74 billion.
GUIDANCE:
Amgen sees FY2023 EPS of $17.40-$18.60, versus the consensus of $18.33. Amgen sees... More
